retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity is gaining attention in metabolic research for its activity on GIP, GLP-1, and receptors. In this carousel, we summarize recent clinical study findings related to weight management, type First-in-Class 'Triple-G'! Retatrutide, a first-in-class

Researchers found that semaglutide users were twice as likely to develop nAMD compared to non-users, even after adjusting for other health factors

Larger Phase 3 trials are required before regulatory approval can be sought, and results in real-world clinical practice may differ from those observed under trial conditions

In the MitoPark mouse, one of the few preclinical models of progressive PD, a clinically translatable dose of exendin-4 reduced the rate of dopaminergic neuronal loss and accompanying motor dysfunction (150), and mitigated mitochondrial dysfunction and loss (151)

GLP-1/GIP medication is the health topic that everyones talking about: whos taking it, why theyre taking it, and who should actually be taking it in the first place

Regulating Blood Sugar Levels: GLP-1 medications promote insulin release from the pancreas when blood sugar is elevated